School of Health Policy and Management, York University, 4700 Keele St., Toronto, ON M3J 1P3, Canada.
Global Health. 2012 Jul 11;8:24. doi: 10.1186/1744-8603-8-24.
Pharmaceutical companies spend huge sums promoting their products whereas regulation of promotional activities is typically underfinanced. Any option for financing the monitoring and regulation of promotion should adhere to three basic principles: stability, predictability and lack of (perverse) ties between the level of financing and performance. This paper explores the strengths and weaknesses of six different models. All these six models considered here have positive and negative features and none may necessarily be ideal in any particular country. Different countries may choose to utilize a combination of two or more of these models in order to raise sufficient revenue. Financing of regulation of drug promotion should more than pay for itself through the prevention of unnecessary drug costs and the avoidance of adverse health effects due to inappropriate prescribing. However, it involves an initial outlay of money that is currently not being spent and many national governments, in both rich and poor countries, are unwilling to incur extra costs.
制药公司在产品推广上投入巨资，而推广活动的监管通常资金不足。任何用于监测和监管推广活动的融资方案都应遵守三个基本原则：稳定性、可预测性以及融资水平与业绩之间不存在（不当）关联。本文探讨了六种不同模式的优缺点。这里考虑的所有六种模式都具有积极和消极的特征，在任何特定国家都不一定是理想的模式。不同国家可能会选择结合使用其中两种或多种模式，以筹集足够的资金。通过防止不必要的药物费用支出和避免因不当处方而产生的不良健康影响，药品推广监管的融资应该能够通过自身实现收支平衡。然而，这需要一笔初始支出，而目前这笔钱尚未支出，许多富国和穷国的政府都不愿意承担额外的费用。
